Loading patent…
AssigneeKeryx Biopharmaceuticals, Inc.
InventorsEnrique Poradosu, Ron Bentsur, James F. Oliviero, III
Estimating the term…
Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration), increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron, reduce the need for erythropoiesis-stimulating agents (ESAs), and/or reduce mortality and morbidity related to adverse cardiac events in chronic kidney disease patients, are disclosed.
A method of reducing mortality and morbidity related to adverse cardiac events in subjects with chronic kidney disease, comprising orally administering ferric citrate to a chronic kidney disease patient in an amount ranging from 1 g to 18 g.
A method of reducing incidence or risk of adverse cardiac events in subjects with chronic kidney disease, comprising orally administering ferric citrate to a chronic kidney disease patient in an amount ranging from 1 g to 18 g.
A method of reducing incidence or risk of hospitalizations related to adverse cardiac events in subjects with chronic kidney disease, comprising orally administering ferric citrate to a chronic kidney disease patient in an amount ranging from 1 g to 18 g.
A method of reducing incidence or risk of sudden cardiac death in subjects with chronic kidney disease, comprising orally administering ferric citrate to a chronic kidney disease patient in an amount ranging from 1 g to 18 g.
A method of treating left ventricular hypertrophy (LVH) in subjects with chronic kidney disease, comprising orally administering ferric citrate to a chronic kidney disease patient in an amount ranging from 1 g to 18 g.
Dependencies are inferred from the claim text.